(ENTA) Enanta Pharmaceuticals - Performance -40% in 12m
ENTA performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-84.35%
#152 in Peer-Group
Rel. Strength
12.38%
#6746 in Stock-Universe
Total Return 12m
-39.95%
#117 in Peer-Group
Total Return 5y
-84.38%
#96 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 16.54 USD |
| 52 Week Low | 4.26 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 88.51 |
| Buy/Sell Signal +-5 | -0.04 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: ENTA (-40%) vs XBI (-6.2%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
2.94% | 73.2% | 77.8% | 22.7 | 13.6 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-9.16% | -5.32% | 147% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
2.99% | -0.49% | 36% | 25.4 | 13.4 | 0.93 | 0.60% | 41% |
| BIM PA Biomerieux |
1.6% | 32.8% | -4.82% | 33.1 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
3.29% | -6.6% | 1.14% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
17.1% | 57.4% | -4.19% | 27.6 | 22.4 | 0.9 | 68.9% | 36.8% |
| PTCT NASDAQ PTC Therapeutics |
-3.2% | 58.3% | -9.25% | 7.71 | 6.26 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
5.64% | 38.5% | 15.2% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: ENTA vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for ENTA
| Total Return (including Dividends) | ENTA | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 9.74% | 3.53% | 5.22% |
| 3 Months | 56.24% | 9.10% | 16.86% |
| 12 Months | -39.95% | -6.17% | 14.81% |
| 5 Years | -84.38% | -24.21% | 111.83% |
| Trend Score (consistency of price movement) | ENTA | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 42.4% | 4.4% | 81% |
| 3 Months | 90.9% | 78.8% | 96.9% |
| 12 Months | -77.3% | -85.8% | 44.9% |
| 5 Years | -79.2% | -52.6% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th73.50 | 5.99% | 4.29% |
| 3 Month | %th85.50 | 43.21% | 33.69% |
| 12 Month | %th41.50 | -36.01% | -47.70% |
| 5 Years | %th52.50 | -79.39% | -92.62% |
FAQs
Does Enanta Pharmaceuticals (ENTA) outperform the market?
No,
over the last 12 months ENTA made -39.95%, while its related Sector, the SPDR S&P Biotech (XBI) made -6.17%.
Over the last 3 months ENTA made 56.24%, while XBI made 9.10%.
Performance Comparison ENTA vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
ENTA vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 2.9% | 4.5% | 35.1% | -55% |
| US NASDAQ 100 | QQQ | 3.2% | 4.1% | 33.9% | -54% |
| German DAX 40 | DAX | 3.9% | 10.4% | 21.7% | -69% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 4.6% | 5.5% | 32.3% | -58% |
| Hongkong Hang Seng | HSI | 3.8% | 3.4% | 16.7% | -75% |
| India NIFTY 50 | INDA | 4.9% | 6.4% | 36.9% | -40% |
| Brasil Bovespa | EWZ | 0.9% | 1.5% | 8.4% | -51% |
ENTA vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 3.6% | 3.2% | 30.4% | -67% |
| Consumer Discretionary | XLY | 2.2% | 6.8% | 43% | -59% |
| Consumer Staples | XLP | 2.6% | 9.8% | 35.2% | -50% |
| Energy | XLE | 3.6% | 4.8% | 40.3% | -38% |
| Financial | XLF | 2.4% | 5.3% | 31.2% | -70% |
| Health Care | XLV | 4.1% | 7.4% | 43.1% | -36% |
| Industrial | XLI | 2.3% | 5.5% | 28.1% | -65% |
| Materials | XLB | 1% | 5.1% | 30.5% | -46% |
| Real Estate | XLRE | 3% | 8.5% | 37.5% | -53% |
| Technology | XLK | 2.7% | 0.9% | 32% | -51% |
| Utilities | XLU | 4.2% | 9.7% | 33.7% | -63% |
| Aerospace & Defense | XAR | 4.1% | 2.1% | 17.9% | -89% |
| Biotech | XBI | 3.2% | 6.2% | 49.2% | -34% |
| Homebuilder | XHB | -0.1% | 1.2% | 43% | -45% |
| Retail | XRT | -0.2% | 5.5% | 39.7% | -51% |
ENTA vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 2.9% | 2.16% | 44.9% | -32% |
| Natural Gas | UNG | 7.7% | 19.8% | 43.6% | -33% |
| Gold | GLD | 4.9% | 10.3% | 15.3% | -81% |
| Silver | SLV | 4.6% | 3.2% | 17.2% | -60% |
| Copper | CPER | 4.4% | 4.7% | 16.5% | -54% |
ENTA vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 5.8% | 7.1% | 39.6% | -39% |
| iShares High Yield Corp. Bond | HYG | 4.6% | 8% | 36.7% | -50% |